Answers are grounded in this paper and cite their sources.
Retrospective analysis shows low relapse rates post-vaccination in NMOSD, suggesting safety of vaccination efforts.
Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%-10.6%]) of physician-reported relapses occurring within 4 weeks of meningococcal vaccination in those screened in CHAMPION-NMOSD (NCT04201262), randomized to eculizumab or placebo in PREVENT (NCT01892345), and from the Japanese postmarketing surveillance of eculizumab in patients with anti-aquaporin-4 antibody-positive NMOSD. Further studies are needed to determine if postvaccination relapses are attributable to vaccination or inherent relapse risk among these patients.
No takes yet. Share an insight, caveat, or question.
Pittock et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: